Skip to main content

Advertisement

Table 3 Baseline characteristics of patients

From: A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment

Characteristics Intratympanic Dex (n = 58) Topical IGF-1 (n = 60) Pvalue
Age-yr, mean ± SD 50.1 ± 13.0 48.6 ± 14.0 0.557
Male sex-no. (%) 26 (44.8) 28 (46.7) 0.855
No. of days for study entry from onset, mean (95% CI) 16.3 (15.1-17.5) 15.8 (14.6-17.0) 0.574
Hearing improvement by pre-treatment-no. (%)    
>10 dB, <30 dB 13 (22.4) 17 (28.3) 0.528
<10 dB 45 (77.6) 43 (71.7)
Hearing-dB pure-tone average, mean (95% CI)    
Affected ear 84.8 (79.1-90.4) 85.6 (80.0-91.2) 0.835
Unaffected ear 15.8 (12.4-19.2) 20.4 (15.0-25.7) 0.160
Other symptoms-no. (%)    
Dizziness/Vertigo 23 (39.7) 31 (51.7) 0.202
Tinnitus 49 (84.5) 51 (85) >0.999
Aural fullness 44 (75.9) 32 (53.3) 0.013*
  1. An asterisk indicates statistical significance with Fisher’s exact test. Dex: dexamethasone.